beta-lapachone has been researched along with paclitaxel in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Bian, J; Dong, Y; Li, X; Wu, X; You, Q; Zhang, X | 1 |
| Li, X; Li, Z; Wu, X; You, Q; Yu, Y; Zhang, X | 1 |
| Abdeen, S; Chapman, E; Chitre, S; Hoang, QQ; Johnson, SM; Park, Y; Ray, AM; Salim, N; Sivinski, J; Stevens, M; Washburn, A | 1 |
| Li, CJ; Li, YZ; Pardee, AB; Pinto, AV | 1 |
| Chang, CC; Chang, HL; Chau, YP; Chen, ST; Kuo, ML; Lin, MT; Su, JL | 1 |
| Augello, G; D'Anneo, A; di Fiore, R; Giuliano, M; Messina, C; Santulli, A; Tesoriere, G; Vento, R | 1 |
| Chen, Z; Gao, J; Liu, C; Qian, F; Yang, K; Zhang, L | 1 |
| Beg, MS; Bolluyt, J; Boothman, DA; Deberardinis, RJ; Fattah, F; Gerber, DE; Huang, X; Laheru, D; Leff, R; Merritt, ME; Sarode, V; Silvers, MA; Xie, XJ | 1 |
| Chen, Z; Huang, N; Liu, Z; Qian, F; Sun, H; Zhang, L | 1 |
| Chang, N; Ge, N; Qian, L; Zhao, Y | 1 |
| Chen, X; Fan, X; Ji, J; Li, L; Xu, W; Zhou, K | 1 |
16 other study(ies) available for beta-lapachone and paclitaxel
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
2-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Furans; Humans; Lung Neoplasms; Models, Molecular; Molecular Structure; NAD(P)H Dehydrogenase (Quinone); Naphthalenes; Oxidation-Reduction; Reactive Oxygen Species; Structure-Activity Relationship | 2017 |
Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Glutathione; Humans; Lung Neoplasms; Mice, Nude; Models, Molecular; NAD(P)H Dehydrogenase (Quinone); Paclitaxel; Poly (ADP-Ribose) Polymerase-1; Quinones; Reactive Oxygen Species; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2018 |
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
Topics: Biological Products; Chaperonin 10; Chaperonin 60; Escherichia coli; Humans; Inhibitory Concentration 50; Protein Folding; Rafoxanide; Salicylanilides; Suramin | 2019 |
Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: combining drugs imposes different artificial checkpoints.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Survival; Cyclin-Dependent Kinases; Drug Synergism; Female; Humans; Mice; Mice, Nude; Naphthoquinones; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1999 |
Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation.
Topics: Active Transport, Cell Nucleus; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Nucleus; Cell Survival; Cysteine-Rich Protein 61; DNA; Doxorubicin; Flow Cytometry; Genes, Dominant; Genes, Reporter; Humans; Immediate-Early Proteins; Integrin alphaVbeta3; Integrins; Intercellular Signaling Peptides and Proteins; Microscopy, Fluorescence; Models, Biological; Naphthoquinones; NF-kappa B; Oligonucleotides, Antisense; Paclitaxel; Promoter Regions, Genetic; Proteins; Receptors, Vitronectin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Time Factors; Transfection; Up-Regulation; X-Linked Inhibitor of Apoptosis Protein | 2004 |
Paclitaxel and beta-lapachone synergistically induce apoptosis in human retinoblastoma Y79 cells by downregulating the levels of phospho-Akt.
Topics: Active Transport, Cell Nucleus; Androstadienes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Caspase 3; Caspase 6; Cell Line, Tumor; Cell Nucleus; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Lamin Type B; Naphthoquinones; Paclitaxel; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Protein Stability; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Retinoblastoma; Time Factors; Transfection; Tumor Suppressor Protein p53; Wortmannin | 2010 |
β-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy as Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy.
Topics: Anti-Infective Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Synergism; Drug Therapy, Combination; Humans; Lung Neoplasms; Micelles; NAD(P)H Dehydrogenase (Quinone); Nanotechnology; Naphthoquinones; Paclitaxel; Pancreatic Neoplasms; Polymers; Tumor Cells, Cultured | 2015 |
Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Deoxycytidine; Gemcitabine; Humans; NAD(P)H Dehydrogenase (Quinone); Naphthoquinones; Paclitaxel; Pancreatic Neoplasms | 2017 |
Intermolecular Interactions between Coencapsulated Drugs Inhibit Drug Crystallization and Enhance Colloidal Stability of Polymeric Micelles.
Topics: Abietanes; Antineoplastic Agents; Chemistry, Pharmaceutical; Colloids; Crystallization; Drug Carriers; Drug Compounding; Drug Synergism; Enzyme Inhibitors; Humans; Micelles; Molecular Dynamics Simulation; NAD(P)H Dehydrogenase (Quinone); Nanoparticles; Naphthoquinones; Paclitaxel; Polyethylene Glycols | 2017 |
A pH/ROS cascade-responsive and self-accelerating drug release nanosystem for the targeted treatment of multi-drug-resistant colon cancer.
Topics: Animals; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Dextrans; Drug Carriers; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Histidine; Humans; Hydrogen-Ion Concentration; Mice; Nanoparticles; Naphthoquinones; Paclitaxel; Prodrugs; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2020 |
A novel multifunctional nanoparticles formed by molecular recognition between AS1411 aptamer and redox-responsive paclitaxel-nucleoside analogue prodrug for combination treatment of β-lapachone and paclitaxel.
Topics: Aptamers, Nucleotide; Cell Line, Tumor; Multifunctional Nanoparticles; Nanoparticles; Naphthoquinones; Nucleosides; Oligodeoxyribonucleotides; Oxidation-Reduction; Paclitaxel; Prodrugs | 2022 |